Karkus

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Retrieved on: 
Tuesday, January 30, 2024
Prophase, Growth, Whole genome sequencing, Therapy, Karkus, Nebula Genomics, Marketing, Genomics, Acquisition, Health, Nebula, WGS

Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

Key Points: 
  • Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
  • This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.
  • In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model.
  • As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
Tuesday, October 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

Retrieved on: 
Thursday, August 3, 2023
Therapy, LB-1, Cancer, Genomics, Burn, Linebacker, Machine learning, Artificial intelligence, Prophase, Karkus, IND, Pharmaceutical industry, Medical device, Certis Group

“We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.

Key Points: 
  • “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
  • “Our team is very pleased to be working with ProPhase on the Linebacker initiative.
  • “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward.
  • We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.

ProPhase Labs to Present at LD Micro Invitational XI Virtual Conference

Retrieved on: 
Friday, May 28, 2021
Dietary Supplements, NASDAQ, Karkus, Finance, Databases, Information science

CEO Ted Karkus to Present at Conference on Thursday, June 10th, 2021

Key Points: 
  • CEO Ted Karkus to Present at Conference on Thursday, June 10th, 2021
    GARDEN CITY, NY, May 28, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that CEO Ted Karkus will present at the LD Micro Invitational XI virtual conference taking place June 8-10, 2021.
  • For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com .
  • ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company.
  • ProPhase Labs researches, develops, manufactures, distributes, markets, and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements brand.

ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York

Retrieved on: 
Friday, January 29, 2021
COVID-19 testing, Clinical Laboratory Improvement Amendments, Karkus, Health, Articles

We are exceptionally proud of our teams rapid buildout of the new lab and successful onboarding of a world-class technical staff for the new facility.

Key Points: 
  • We are exceptionally proud of our teams rapid buildout of the new lab and successful onboarding of a world-class technical staff for the new facility.
  • Our strategic rollout of CLIA Labs is proceeding exactly as planned, said Ted Karkus, CEO of ProPhase Labs.
  • In addition to COVID-19 testing, we are looking to diversify into other areas of high margin diagnostic molecular testing, explained Karkus.
  • At ProPhase Diagnostics, Steve will be responsible for ensuring the company meets its stated goal of 60,000 tests per day between its Garden City, New York lab and Old Bridge, New Jersey lab.